Abstract
The conversion of skeletal myoblasts to terminally differentiated myocytes is negatively controlled by several growth factors and oncoproteins. In this study, we have investigated the molecular mechanisms by which v-Src, a prototypic tyrosine kinase, perturbs myogenesis in primary avian myoblasts and in established murine C2C12 satellite cells. We determined the expression levels of the cell cycle regulators pRb, cyclin D1 and D3 and cyclin-dependent kinase inhibitors p21 and p27 in v-Src-transformed myoblasts and found that, in contrast to myogenin, they are normally modulated by differentiative cues, implying that v-Src affects myogenesis independent of cell proliferation. We then examined the levels of expression, DNA-binding ability and transcription-activation potentials of myogenic regulatory factors in transformed myoblasts and in myotubes after reactivation of a temperature-sensitive allele of v-Src. Our results reveal two distinct potential modes of repression targeted to myogenic factors. On the one hand, we show that v-Src reversibly inhibits the expression of MyoD and myogenin in C2C12 cells and of myogenin in quail myoblasts. Remarkably, these loci become resistant to activation of the kinase in the postmitotic compartment. On the other hand, we demonstrate that v-Src efficiently inhibits muscle gene expression by repressing the transcriptional activity of myogenic factors without affecting MyoD DNA-binding activity. Indeed, forced expression of MyoD and myogenin allows terminal differentiation of transformed myoblasts. Finally, we found that ectopic expression of the coactivator p300 restores transcription from extrachromosomal muscle-specific promoters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alberts AS, Geneste O and Treisman R . (1998). Cell, 92, 475–487.
Alemà S and Tatò F . (1994). Semin. Cancer Biol., 5, 147–156.
Andres V and Walsh K . (1996). J. Cell Biol., 132, 657–666.
Boettiger D . (1989). Curr. Top. Microbiol. Immunol., 147, 31–78.
Caruso M, Martelli F, Giordano A and Felsani A . (1993). Oncogene, 8, 267–278.
Castellani L, Reedy M, Airey JA, Gallo R, Ciotti MT, Falcone G and Alemà S . (1996). J. Cell Sci., 109, 1335–1346.
Castellani L, Reedy MC, Gauzzi MC, Provenzano C, Alemà S and Falcone G . (1995). J. Cell Biol., 130, 871–885.
Chan HM and La Thangue NB . (2001). J. Cell Sci., 114, 2363–2373.
Crescenzi M, Fleming TP, Lassar AB, Weintraub H and Aaronson SA . (1990). Proc. Natl. Acad. Sci. USA, 87, 8442–8446.
de la Serna IL, Carlson KA and Imbalzano AN . (2001a). Nat. Genet., 27, 187–190.
de la Serna IL, Roy K, Carlson KA and Imbalzano AN . (2001b). J. Biol. Chem., 276, 41486–41491.
Eckner R, Yao TP, Oldread E and Livingston DM . (1996). Genes Dev., 10, 2478–2490.
Falcone G, Alemà S and Tatò F . (1991). Mol. Cell Biol., 11, 3331–3338.
Falcone G, Boettiger D, Alemà S and Tatò F . (1984). EMBO J., 3, 1327–1331.
Gallo R, Provenzano C, Carbone R, Di Fiore PP, Castellani L, Falcone G and Alemà S . (1997). Oncogene, 15, 1929–1936.
Gallo R, Serafini M, Castellani L, Falcone G and Alemà S . (1999). Mol. Cell. Biol., 10, 3137–3150.
Gossett LA, Kelvin DJ, Sternberg EA and Olson EN . (1989). Mol. Cell. Biol., 9, 5022–5033.
Guo K, Wang J, Andres V, Smith RC and Walsh K . (1995). Mol Cell. Biol., 15, 3823–3829.
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D and Lassar AB . (1995). Science, 267, 1018–1021.
Iezzi S, Cossu G, Nervi C, Sartorelli V and Puri PL . (2002). Proc. Natl. Acad. Sci. USA, 99, 7757–7762.
Jen Y, Weintraub H and Benezra R . (1992). Genes Dev., 6, 1466–1479.
Johnson SE, Dorman CM and Bolanowski SA . (2002). J. Biol. Chem., 277, 28742–28748.
Johnston LA, Tapscott SJ and Eisen H . (1992). Mol. Cell. Biol., 12, 5123–5130.
Kiess M, Gill RM and Hamel PA . (1995). Oncogene, 10, 159–166.
Kong Y, Johnson SE, Taparowsky EJ and Konieczny SF . (1995). Mol. Cell. Biol., 15, 5205–5213.
Konieczny SF, Drobes BL, Menke SL and Taparowsky EJ . (1989). Oncogene, 4, 473–481.
La Rocca SA, Vannucchi S, Pompili M, Pinney DF, Emerson Jr CP, Grossi M and Tato F . (2002). Oncogene, 21, 4838–4342.
Lassar AB, Buskin JN, Lockshon D, Davis RL, Apone S, Hauschka SD and Weintraub H . (1989a). Cell, 58, 823–831.
Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, Baltimore D and Weintraub H . (1991). Cell, 66, 305–315.
Lassar AB, Thayer MJ, Overell RW and Weintraub H . (1989b). Cell, 58, 659–667.
Lazaro JB, Bailey PJ and Lassar AB . (2002). Genes Dev., 16, 1792–1805.
Liu LN, Dias P and Houghton PJ . (1998). Cell Growth Differ., 9, 699–711.
Maione R and Amati P . (1997). Biochim. Biophys. Acta., 1332, M19–M30.
Martelli F, Cenciarelli C, Santarelli G, Polikar B, Felsani A and Caruso M . (1994). Oncogene, 9, 3579–3590.
Miner JH and Wold BJ . (1991). Mol. Cell. Biol., 11, 2842–2851.
Molkentin JD and Olson EN . (1996). Proc. Natl. Acad. Sci. USA, 93, 9366–9373.
Olson EN and Klein WH . (1994). Genes Dev., 8, 1–8.
Perry RL, Parker MH and Rudnicki MA . (2001). Mol. Cell, 8, 291–301.
Perry RL and Rudnicki MA . (2000). Front. Biosci., 5, D750–D767.
Pinney DF, de la Brousse FC, Faerman A, Shani M, Maruyama K and Emerson Jr CP . (1995). Dev. Biol., 170, 21–38.
Polesskaya A, Duquet A, Naguibneva I, Weise C, Vervisch A, Bengal E, Hucho F, Robin P and Harel-Bellan A . (2000). J. Biol. Chem., 275, 34359–34364.
Pownall ME and Emerson CP . (1992). Dev. Biol., 151, 67–79.
Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A and Levrero M . (1997a). EMBO J., 16, 369–383.
Puri PL, Bhakta K, Wood LD, Costanzo A, Zhu J and Wang YJ . (2002). Nat. Genet., 32, 585–593.
Puri PL and Sartorelli V . (2000). J. Cell. Physiol., 185, 155–173.
Puri PL, Sartorelli V, Yang X-J, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JYJ, Graessmann A, Nakatani Y and Levrero M . (1997b). Mol. Cell, 1, 35–45.
Ramocki MB, Johnson SE, White MA, Ashendel CL, Konieczny SF and Taparowsky EJ . (1997). Mol. Cell. Biol., 17, 3547–3555.
Roy K, se la Serna IL and Imbalzano AN . (2002). J. Biol. Chem., 277, 33818–33824.
Russo S, Tatò and Grossi M . (1997). Oncogene, 14, 63–73.
Sartorelli V, Huang J, Hamamori Y and Kedes L . (1997). Mol. Cell. Biol., 17, 1010–1026.
Sartorelli V, Puri PL, Hamamori Y, Ogryzko V, Chung G, Nakatani Y, Wang JY and Kedes L . (1999). Mol. Cell, 4, 725–734.
Skapek SX, Rhee J, Spicer DB and Lassar AB . (1995). Science, 267, 1022–1024.
Sternberg EA, Spizz G, Perry WM, Vizard D, Weil T and Olson EN . (1988). Mol. Cell. Biol., 8, 2896–2909.
Thomas SM and Brugge JS . (1997). Annu. Rev. Cell. Dev. Biol., 13, 513–609.
Vaidya TB, Rhodes SJ, Taparowsky EJ and Konieczny SF . (1989). Mol. Cell. Biol., 9, 3576–3579.
Walsh K and Perlman H . (1997). Curr. Opin. Genet. Dev., 7, 1377–1386.
Wei Q and Paterson BM . (2001). FEBS Lett., 490, 171–178.
Weintraub H, Dwarki VJ, Verma I, Davis R, Hollenberg S, Snider L, Lassar A and Tapscott SJ . (1991). Genes Dev., 5, 1377–1386.
Welham MJ, Wyke JA, Lang A and Wyke AW . (1990). Oncogene, 5, 161–169.
Winter B and Arnold H-H . (2000). J. Cell Sci., 113, 4211–4220.
Yoon H and Boettiger D . (1994). Oncogene, 9, 801–807.
Zabludoff SD, Csete M, Wagner R, Yu X and Wold BJ . (1998). Cell Growth Differ., 9, 1–11.
Zhang JM, Wei Q, Zhao X and Paterson BM . (1999). EMBO J., 18, 926–933.
Acknowledgements
We thank all the colleagues who generously provided plasmids and antibodies and M Crescenzi, M Caruso and M Grossi for discussion and critical reading of the manuscript. This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Progetto Finalizzato Biotecnologie (CNR), Progetto Coordinato-Agenzia 2000 (CNR) and MIUR (Cofin).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Falcone, G., Ciuffini, L., Gauzzi, MC. et al. v-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels. Oncogene 22, 8302–8315 (2003). https://doi.org/10.1038/sj.onc.1206915
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206915
Keywords
This article is cited by
-
Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases
Scientific Reports (2016)
-
Delineating v-Src downstream effector pathways in transformed myoblasts
Oncogene (2008)
